Skip to Main Content
Our COVID-19 ResponseLearn More

Sawai Receives Approvals for Two Generic Drugs with Five Strengths

Osaka, Japan – August 15, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for two generic drugs with five strengths. The two compounds, Aprepitant and Micafungin Sodium are approved for the first time as generics.

The list of approved products:

Aprepitant Capsules 80 mg [SAWAI], 125 mg [SAWAI] and Capsule Set[SAWAI]

  • Generic name: Aprepitantt
  • Indications: Digestive symptoms (nausea, vomiting) resulting from the administration of antineoplastic
    agents (cisplatin, etc.) (including in delayed phase)
  • Brand products: EMEND® Capsules 80 mg, 125 mg and Capsule Set
  • Brand products: Funguard® 25 mg, 50 mg and 75 mg for Infusion

Micafungin Na 50 mg [SAWAI] for Infusion and 75 mg [SAWAI] for Infusion

  • Generic name: Micafungin Sodium
  • Indications: Infections caused by Aspergillus sp. and Candida sp. such as fungemia, respiratory
    mycosis and gastrointestinal mycosis
  • Brand products: Funguard® 25 mg, 50 mg and 75 mg for Infusion

The products announced in this press release are not approved by the Food & Drug
Administration for sale and distribution in the United States.

About Sawai

Founded in 1929, Sawai Pharmaceutical Co., Ltd. has grown into one of the leading generics companies in Japan.
Guided by its corporate philosophy, “Always Putting Patients First,” Sawai markets more than 310 high-quality generic drugs with 760 strengths and reliably delivers them to patients throughout Japan. In 2017, Sawai acquired US-based Upsher-Smith Laboratories, LLC marking its first step in overseas expansion to become a globally recognized generic pharmaceutical company. For more information, visit: https://www.sawai.co.jp/en/.

For further information please contact:
PR/IR group, pr@sawai.co.jp

Download Press Release